183 related articles for article (PubMed ID: 22901018)
1. Private manufacturers' thresholds to invest in comparative effectiveness trials.
Basu A; Meltzer D
Pharmacoeconomics; 2012 Oct; 30(10):859-68. PubMed ID: 22901018
[TBL] [Abstract][Full Text] [Related]
2. The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.
Meltzer D; Basu A; Conti R
Pharmacoeconomics; 2010; 28(10):843-53. PubMed ID: 20831292
[TBL] [Abstract][Full Text] [Related]
3. Assessing the long-term impact of public investments in comparative effectiveness research: conceptual framework and lessons learned.
Rich EC; Esposito D; Kimmey LD; Valenzano CS; Yong PL
J Comp Eff Res; 2014 Nov; 3(6):657-66. PubMed ID: 25494572
[TBL] [Abstract][Full Text] [Related]
4. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Can CER be an effective tool for change in the development and assessment of new drugs and technologies?
Brixner DI; Watkins JB
J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S06-11. PubMed ID: 22663293
[TBL] [Abstract][Full Text] [Related]
7. The ARRA investment in CER: a description of the midstream evaluation and how the funds were allocated and CER priorities addressed.
Esposito D; Yong PL; Rich E; Geonnotti K; Kimmey LD
J Comp Eff Res; 2014 Nov; 3(6):581-9. PubMed ID: 25494564
[TBL] [Abstract][Full Text] [Related]
8. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
Milne CP; Cohen JP; Felix A; Chakravarthy R
Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
[TBL] [Abstract][Full Text] [Related]
9. Lessons from comparative effectiveness research methods development projects funded under the Recovery Act.
Zurovac J; Esposito D
J Comp Eff Res; 2014 Nov; 3(6):601-7. PubMed ID: 25494566
[TBL] [Abstract][Full Text] [Related]
10. Looking at CER from the pharmaceutical industry perspective.
Dubois RW
J Manag Care Pharm; 2012 May; 18(4 Suppl A):S9-12. PubMed ID: 22578212
[TBL] [Abstract][Full Text] [Related]
11. The role of private industry in pragmatic comparative effectiveness trials.
Buesching DP; Luce BR; Berger ML
J Comp Eff Res; 2012 Mar; 1(2):147-56. PubMed ID: 24237375
[TBL] [Abstract][Full Text] [Related]
12. An investment appraisal approach to clinical trial design.
Backhouse ME
Health Econ; 1998 Nov; 7(7):605-19. PubMed ID: 9845254
[TBL] [Abstract][Full Text] [Related]
13. PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH.
Moloney R; Mohr P; Hawe E; Shah K; Garau M; Towse A
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):90-8. PubMed ID: 26168804
[TBL] [Abstract][Full Text] [Related]
14. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
Sorenson C
Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
[TBL] [Abstract][Full Text] [Related]
15. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
Pekarsky B
Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness research in the United States: a progress report.
Sullivan SD; Carlson JJ; Hansen RN
J Med Econ; 2013; 16(2):295-7. PubMed ID: 23227997
[TBL] [Abstract][Full Text] [Related]
17. Integrating economic evaluation methods into clinical and translational science award consortium comparative effectiveness educational goals.
Iribarne A; Easterwood R; Russo MJ; Wang YC
Acad Med; 2011 Jun; 86(6):701-5. PubMed ID: 21512372
[TBL] [Abstract][Full Text] [Related]
18. Leveraging observational registries to inform comparative effectiveness research.
Shah BR; Drozda J; Peterson ED
Am Heart J; 2010 Jul; 160(1):8-15. PubMed ID: 20598966
[TBL] [Abstract][Full Text] [Related]
19. What does US$1.1 billion buy? An investment in the future.
Simpson LA
J Comp Eff Res; 2014 Nov; 3(6):561-3. PubMed ID: 25494559
[No Abstract] [Full Text] [Related]
20. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
Mullins CD; Sanchez RJ
J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
